The prognostic value of ctDNA in NSCLC treated with neoadjuvant chemoimmunotherapy

The single-arm, open label Phase II NADIM study (NCT03081689) aimed to evaluate neoadjuvant nivolumab immunotherapy plus chemotherapy in patients with resectable stage IIIA non-small cell lung cancer (NSCLC). Atocha Romero, PhD, Hospital Universitario Puerta De Hierro, Madrid, Spain, describes the results of an exploratory analysis of the NADIM study which demonstrated the prognostic value of pre-treatment levels of circulating tumor DNA (ctDNA) in identifying patients with NSCLC at high risk of progression and offers potential as a surrogate marker for long-term survival in the adjuvant setting. Dr Romero also explains the importance of standardizing the procedures and technologies used for ctDNA quantification. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.